

# Medicare Ponders 'Medically Unbelievable Edits'

BY JOYCE FRIEDEN  
Senior Editor

WASHINGTON — If you don't like medically "unbelievable" edits, how about medically "unusual" ones?

Members of the Practicing Physicians Advisory Council (PPAC), which advises the Centers for Medicare and Medicaid Services (CMS) on issues of interest to physicians, were upset about the name of the proposed Medically Unbelievable Edits

program, which aims to find obvious errors in Medicare claims—for example, a claim for doing a hysterectomy on a male patient.

"'Unbelievable' is a value judgment," PPAC member Dr. Peter Grimm, a radiation oncologist from Seattle, said at a recent council meeting. "You're going to get immediate reaction from people, so changing that word to 'unusual' doesn't change your [acronym] and really accurately describes what you're trying to do."

PPAC member Dr. M. LeRoy Sprang, an

Evanston, Ill., ob.gyn., had another idea. "How about 'medically unexpected?' It's a softer word, and it really covers what you want to do. It's just not as obnoxious as 'unbelievable.'"

The program in question is designed to detect implausible Medicare claims submissions and avert inappropriate claims payment, according to Lisa Zone, director of the program integrity group at the CMS Office of Financial Management.

"I realize that this is an unfortunate title,"

she said. "We are trying to install edits to detect true errors in the system."

A recent CMS report found that Medicare's national paid claims error rate was 5.1%, "and we know that 1.7% is related to improper coding or billing errors," Ms. Zone said. "When you look at the federal dollars expended in the coding error class, it's in the billions of dollars."

The comment period for the proposed program ended on June 19, and Ms. Zone noted that "given that we've [already]

For the treatment of hyperkeratosis

Patients Feel More Comfortable  
in Their Skin With...

## New U-Kera E™ Urea Emollient Cream, 40%

- emollient cream moisturizes
- urea exfoliates
- formulated with 2% glycolic acid
- low residue<sup>1</sup>, easy-to-spread<sup>1</sup> vehicle

For samples, call  
1-877-537-2655

Visit [www.U-KeraE.com](http://www.U-KeraE.com)

U-Kera E is contraindicated in patients with known hypersensitivity to any of the listed ingredients. Local adverse reactions that may occur and normally disappear on discontinuing use include transient stinging, burning, itching and irritation. If redness or irritation occurs, discontinue use. Contact with eyes, lips or mucous membranes should be avoided.

Please see full Prescribing Information on adjacent page.

<sup>1</sup> Data on file. Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY.



©2006 Taro Pharmaceuticals U.S.A., Inc.

All rights reserved.

April 2006

AD500-0002-R1


### U-Kera E™ Urea Emollient Cream, 40%

Rx only

FOR TOPICAL USE ONLY.  
NOT FOR OPHTHALMIC USE.

**DESCRIPTION:** U-Kera E™ is a keratolytic emollient which is a gentle, yet potent, tissue softener for nails and/or skin. Each gram of U-Kera E™ contains urea USP (40%), purified water USP, light mineral oil NF, white petrolatum USP, glycolic acid, propylene glycol USP, triethylamine NF, glyceryl stearate SE, cetyl alcohol NF, L-arginine USP, and xanthan gum NF.

**CHEMICAL STRUCTURE:**



**CLINICAL PHARMACOLOGY:** Urea gently dissolves the intercellular matrix which results in loosening the horny layer of skin and shedding scaly skin at regular intervals, thereby softening hyperkeratotic areas. Urea also hydrates and gently dissolves the intercellular matrix of the nail plate, which can result in the softening and eventual debridement of the nail plate.

**PHARMACOKINETICS:** The mechanism of action of topically applied urea is not yet known.

**INDICATIONS AND USES:** For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails.

**CONTRAINDICATIONS:** Known hypersensitivity to any of the listed ingredients.

**WARNINGS:** For external use only. Avoid contact with eyes, lips or mucous membranes.

**PRECAUTIONS:** This medication is to be used as directed by a physician and should not be used to treat any condition other than that for which it was prescribed, if redness or irritation occurs, discontinue use.

**PREGNANCY:** Pregnancy Category C. Animal reproduction studies have not been conducted with U-Kera E™. It is also not known whether U-Kera E™ can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. U-Kera E™ should be given to a pregnant woman only if clearly needed.

**NURSING MOTHERS:** It is not known whether or not this drug is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when U-Kera E™ is administered to a nursing woman.

**KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.**

**ADVERSE REACTIONS:** Transient stinging, burning, itching and irritation may occur and normally disappear on discontinuing the medication.

**DOSAGE AND ADMINISTRATION:** Apply U-Kera E™ to affected areas. Protect surrounding tissue. Smooth over affected tissue, nail or skin area(s) until cream is absorbed. If desired, cover with adhesive bandage or gauze, secured with adhesive tape. When applying to diseased or damaged nail surfaces, use an ample amount. Cover as above. An option is then to remove a "finger" from a plastic or vinyl glove and slip over the bandage-covered site. Secure glove finger with additional adhesive tape. Keep dry and occlusive for 3-7 days.

**HOW SUPPLIED:** U-Kera E™ Urea Cream, 40% is supplied in tubes containing 28.35 g (1 oz) NDC 51672-1329-2, 85.05 g (3 oz) NDC 51672-1329-6, and 138.45 g (7 oz) NDC 51672-1329-7. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from freezing.

Mfd. by: Taro Pharmaceuticals Inc.  
Brampton, Ontario, Canada L6T 1C1

Dist. By: TaroPharma  
A division of Taro Pharmaceuticals U.S.A., Inc.  
Hawthorne, NY 10532

U-Kera E™ and TaroPharma® are trademarks of Taro Pharmaceuticals U.S.A., Inc. and/or its affiliates.  
U-Kera E™ is sold by Taro Pharmaceuticals U.S.A., Inc. under license from Medicis Pharmaceutical Corporation.

Revised: January, 2006



a division of Taro Pharmaceuticals U.S.A., Inc.  
3 Skyline Drive, Hawthorne, NY 10532  
1-888-TARO-USA (827-6872)  
Fax: 1-800-329-TARO (8276)  
[www.taropharma.com](http://www.taropharma.com)

heard from various provider organizations about the MUEs out there today for comment, we are not going to be going forward with the MUEs as they are."

Instead, the office will look at the edits as a whole and make decisions on the best way to move forward. Initially, Ms. Zone's office will concentrate on developing edits to catch "anatomical" errors, such as procedures performed on the wrong body part. Then, they will address edits for typographical errors—someone bills for 500 units instead of 5, for example.

After making those changes, the proposal will go out for more comments. The MUEs will not be implemented until at least January of next year, and there will be a "test period" beforehand, Ms. Zone said. The testing will include an appeals process as well as the use of modifiers. Implementation will be in a "staged" approach, starting with the anatomical and typographical edits.

"We're very interested in what you have to say," Ms. Zone told the council. "We want to have those edits detect errors within the claims processing system, but in no way do we want the edits to affect medical practice or payment policy."

Ms. Zone noted that doctors who make errors will not be on any "hit list."

"Certainly, if we see a group or provider who was hitting edits more frequently than anyone else, then a contractor might decide to do some education or medical reviews for someone who was having problems submitting claims correctly, but that would be found based on data analysis," she said.

Council member Dr. Carlos Hamilton, an endocrinologist and executive vice president for clinical affairs at the University of Texas Health Science Center in Houston, told Ms. Zone that "there is considerably more angst in the medical community about this issue than may immediately appear." He noted that while the idea of using anatomical edits seems workable, there are often exceptions.

For example, one possible edit would return a claim if a surgeon took out two spleens in the same patient on the same day. "I'm not a surgeon, but [I know that] there are some people who do have accessory spleens, and it is conceivable that you might have to take out a second spleen," he said. "I really think you need to come up with a modifier for situations that don't appear to be straightforward before you bring this [system] out."

Thomas Gustafson, Ph.D., deputy director of the agency's Center for Medicare Management, seemed sympathetic to the modifier idea. "Insofar as we're capturing inversions of numbers or stuff like that, which are true coding errors, everybody should be able to agree with that," he said. "We then need to isolate those cases that are not essentially expected to arise in the routine practice of medicine. We've got to have some way of addressing that, some modifier or something of that sort."

He added that although CMS expects to save some money with the MUE initiative, "that's not what's driving this... The intent is truly to try to take care of the hysterectomies on men and those kinds of circumstances and try to do it in a sophisticated way so that we're not interfering with the practice of medicine to a noticeable extent." ■

## Systems Issues Exacerbate Malpractice Claims

BY MARY ELLEN SCHNEIDER  
New York Bureau

PHILADELPHIA — There are just as many systems failures at the root of malpractice cases as individual errors or negligence, Dr. Luke Sato said at the annual meeting of the American College of Physicians.

For example, the Risk Management Foundation of the Harvard Medical Institutes Inc., the insurance carrier for 18 hospitals and about 10,000 physicians in

the Massachusetts area, has spent nearly the same amount of money over the years on malpractice cases involving clinical support processes as on cases resulting from a problem with the patient-clinician interaction. "What we see is that this is a process reengineering problem," said Dr. Sato, assistant professor of medicine at Harvard University and chief medical officer and vice president of the Risk Management Foundation.

An analysis of 2,270 malpractice cases within the insurance carrier from Sep-

tember 1995 to August 2005 shows that there are four high-risk categories in the system—obstetrics, surgery, medication-related problems, and diagnosis-related problems. Dr. Sato advised physicians to take a look at their office processes and set up ways within the practice to gather and document information that is critical to both the continuity of care and to avoiding malpractice claims. ■

Examples of best practices from the system are given online at [www.rmfi.harvard.edu](http://www.rmfi.harvard.edu).

In the treatment of mild to moderate rosacea

# RESULTS MATTER



Week after week after week, dermatologists and patients see the benefits of FINACEA\*



Baseline



After 4 weeks of FINACEA bid

[www.finacea-us.com](http://www.finacea-us.com)

FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

Please see brief summary of Prescribing Information on following page.

Results shown are the results for one patient.  
Not all patients may have the same results.

\*FINACEA was only studied in clinical trials for 12 weeks.

**Finacea**<sup>®</sup>  
(azelaic acid) Gel, 15%

Seeing is Believing